Mesoblast Limited

NASDAQ:MESO

Biotechnology

Healthcare
$11.64 +1.86%

+$0.26 today

Market cap
$1.51B
Beta
0.79
P/E (TTM)
-23.6
EPS (TTM)
-$0.06
52W Low $9.88High $21.50

Volume 0.13M

Average 0.21M

MESO Short-term Investments

Marketable securities and deposits the company expects to convert to cash within a year.

Mesoblast LimitedNASDAQ: MESO

Short-term Investments · Q4 FY2026 · quarter ended Jun 2026

Short-term investments remains negative

Q4 FY2026 short-term investments was $0, compared with $0 a year earlier.

Context

  • Short-term investments amounted to 0.0% of total assets at the end of Q4 FY2026, unchanged from a year earlier.
  • Short-term investments increased in 0 of the last 3 fiscal years.
  • FY2026 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearJun 2026
$0— YoY
Year agoJun 2025
$0— since
Short-term Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Short-term Investments history

USD · from the balance sheet

Latest · FY2026
0 USD
Year-over-year change
—

Short-term Investments vs competitors

How MESO compares with its peers on the latest reported figures

  • MESO's Jun 2026 short-term investments of $0 is the 5th highest of the 6 companies compared; the peer median is $135.25M.
  • Short-term investments amounts to 0.0% of total assets for MESO, versus a peer median of 23.3%.
MESO Competitors Peer median
Short-term Investments for MESO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
LEGNLegend Biotech CorporationSep 2026$391.8M -45.1%-42.0%23.3%
CAPRCapricor Therapeutics, Inc.Mar 2026$173.19M +49.3%-1.6%53.1%
FATEFate Therapeutics, Inc.Mar 2026$135.25M -30.8%-25.2%47.5%
LCTXLineage Cell Therapeutics, Inc.Mar 2026$17.44M +91700.0%-31.4%15.9%
MESOMesoblast LimitedJun 2026$0 ——0.0%
CELUCelularity Inc.Dec 2025$0 ——0.0%
Peer median (excluding MESO) $135.25M+9.3%-28.3%23.3%

Competitors are the stored peer set for MESO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
FY2026
Jun 2026
Cash & Equivalents60.03M70.92M62.56M161.16M47.39M
Short-term Investments00000
Net Receivables4.4M7M20.95M14.87M57.66M
Inventory00022.25M28.11M
Other Current Assets413K398K397K393K55.52M
Total Current Assets69.84M81.66M86.46M204.35M197.49M
Property, Plant & Equipment (Net)9.97M6.49M3.84M5.82M8.01M
Goodwill134.45M134.45M134.45M134.45M134.45M
Intangible Assets444.2M442.73M441.28M437.37M431.92M
Long-term Investments1.76M1.76M1.01M1.39M0
Tax Assets252K1.85M000
Other Non-current Assets1.68M481K2.1M1.3M1.2M
Total Non-current Assets592.31M587.76M582.69M580.33M575.59M
Total Assets662.14M669.42M669.15M784.68M773.08M
Account Payables23.08M20.15M7.07M19.08M34.51M
Short-term Debt5.02M5.95M13.86M54.16M10.6M
Tax Payables00000
Deferred Revenue17.91M6.4M000
Other Current Liabilities2.19M5.43M49.69M26.71M20.68M
Total Current Liabilities51.37M41.98M73.24M102.63M81.11M
Long-term Debt91.62M102.81M100.48M67.74M108.64M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities15.02M19.11M13.12M13.29M9.86M
Total Non-current Liabilities113.73M125.6M115.56M84.62M123.56M
Total Liabilities165.1M167.58M188.8M187.24M204.67M
Common Stock1.17B1.25B1.31B1.51B1.53B
Retained Earnings(738.92M)(820.81M)(908.76M)(1.01B)(1.07B)
Accumulated OCI70.65M73.52M78.3M99.5M106.03M
Other Stockholders Equity00000
Minority Interest00000
Total Equity497.04M501.84M480.36M597.44M568.41M
Total Debt106.91M116.5M118.92M128.16M127.33M
Net Debt46.87M45.58M56.36M(33M)79.94M

Mesoblast Limited

NASDAQ:MESO

Intrinsic Alpha fair value

Locked

Current Price

$11.64

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.